X4 Pharmaceuticals(US:XFOR)2025-11-05 13:05Financial Performance - Net product sales for Q3 2025 were $1.6 million, compared to $0.6 million in Q3 2024, representing a 166.7% increase[4] - Total revenue for the nine months ended September 30, 2025, was $32.5 million, significantly up from $1.1 million in the same period of 2024[15] - The operating loss for Q3 2025 was $27.5 million, an improvement from a loss of $34.5 million in Q3 2024, reflecting the impact of strategic restructuring[4] - The net loss for Q3 2025 was $29.8 million, or $0.69 per share, compared to a net loss of $36.7 million, or $5.48 per share, in Q3 2024[7] Funding and Financial Position - The company successfully raised $240.3 million through two financings, extending its cash runway to the end of 2028[2] - Cash, cash equivalents, and short-term investments totaled $122.2 million as of September 30, 2025[8] - Total stockholders' equity increased to $61.6 million as of September 30, 2025, up from $22.1 million at the end of 2024[16] Operational Changes - The workforce was reduced by 50%, expected to generate approximately $13 million in annualized cost savings[5] - The enrollment target for the 4WARD Phase 3 trial has been increased to 176 patients, with completion expected in Q3 2026[5] Market Potential - The potential addressable market for mavorixafor in chronic neutropenia is estimated at 15,000 patients in the US[2]